In this issue:
Pembrolizumab ±RT for metastatic NSCLC
Post-progression outcomes in NSCLC with PD-L1 ≥50% treated with pembrolizumab
Resistance mechanisms of second-line osimertinib in NSCLC
Outcomes and characteristics of patients with KRAS-G12C-mutated NSCLC
Prognostic impact of KRAS-G12C mutation in NSCLC
Durvalumab for stage III EGFR-mutated NSCLC after chemo-RT
CT lung cancer screening guidelines/models performance for rescue/recovery workers
Training oncology care providers in empathic communication skills
Long-term ICI efficacy in NSCLC with MET exon 14 skipping mutations
Using NGS in the real world for managing lung adenocarcinoma
Please login below to download this issue (PDF)